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INTRODUCTION
Autosomal recessive limb-girdle muscular dystrophy (ARL-
GMD) is a clinically and genetically heterogeneous disorder
affecting mainly the pelvic and shoulder girdle muscles. Accor-
ding to the genetic classification of ARLGMD, it has been
divided into ten subtypes, from LGMD type 2A to LGMD
type 2J (1). LGMD type2B (LGMD2B) is caused by muta-
tions in the dysferline gene (DYSF, MIM*603009) located
on chromosome 2p13.3, which induces a dysfunction of dysfer-
lin at the protein level (2). Dysferlin is a member of the FER-
1 protein family and contains six putative C2 domains, which
can bind to phospholipids, inositol polyphosphates, Ca2+ and
intracellular proteins (3). Dysferlin is expressed predominant-
ly in the skeletal muscle and localizes to the plasma mem-
brane of the muscle fibers. In addition, it has been suggest-
ed to be involved in membrane fusion (4, 5). A recent ani-
mal study has suggested that dysferlin plays a role in the sar-
colemma repair process (6). The DYSF has been also shown
to cause Miyoshi myopathy (MM), which is a rare form of
distal myopathy with  the calf muscles weakness. Identical
mutations in patients with LGMD2B or Miyoshi myopathy
have been noted in several reports, suggesting a role for the
modifier gene(s) (7-11). Both LGMD2B and Miyoshi myopa-
thy are referred to as “dysferlinopathy” because of the deficien-
cy of the same protein. 
Because of the clinical and genetic heterogeneity of the
LGMD, the LGMD subtypes are classified based on genetic
or protein analysis. The development of antibodies directed
against dysferlin has recently been shown to be useful for
making a diagnosis of LGMD2B by an examination of a mus-
cle biopsy with immunostaining or immunoblotting tech-
niques (4, 5, 10). In the current study, immunocytochemi-
cal examination for dysferlin was tested on a muscle biopsies
from 17 Korean ARLGMD patients, and the clinical and
pathological characteristics of four Korean LGMD2B patients,
who showed the complete loss of the dysferlin protein on a
muscle biopsy, were investigated. 
MATERIALS AND METHODS
Patients Selection and Muscle biopsy
From March 2001 to November 2002, 17 unrelated, non-
consanguineous LGMD patients were enrolled in this study.
The diagnosis of LGMD was established by the clinical his-
tory and physical examination, the family history, a normal
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Clinical and Pathological Characteristics of Four Korean Patients with
Limb-Girdle Muscular Dystrophy type 2B
Limb-girdle muscular dystrophy type 2B (LGMD2B), a subtype of autosomal reces-
sive limb-girdle muscular dystrophy (ARLGMD), is characterized by a relatively late
onset and slow progressive course. LGMD2B is known to be caused by the loss of
the dysferlin protein at sarcolemma in muscle fibers. In this study, the clinical and
pathological characteristics of Korean LGMD2B patients were investigated. Seven-
teen patients with ARLGMD underwent muscle biopsy and the histochemical exami-
nation was performed. For the immunocytochemistry, a set of antibodies against
dystrophin,  ,  ,  ,  -sarcoglycans, dysferlin, caveolin-3, and  -dystroglycan was
used. Four patients (24%) showed selective loss of immunoreactivity against dysfer-
lin at the sarcolemma on the muscle specimens. Therefore, they were classified into
the LGMD2B category. The age at the onset of disease ranged from 9 yr to 33 yr,
and none of the patients was wheelchair bound at the neurological examination. The
serum creatine kinase (CK) was high in all the patients (4010-5310 IU/L). The patho-
logic examination showed mild to moderate dystrophic features. These are the first
Korean LGMD2B cases with a dysferlin deficiency confirmed by immunocytochem-
istry. The clinical, pathological, and immunocytochemical findings of the patients with
LGMD2B in this study were in accordance with those of other previous reports.
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nerve conduction study and the myopathic pattern on elec-
tromyography (12). All the patients underwent an open biop-
sy from the quadriceps femoris or biceps brachii muscle under
local anesthesia. In all the cases, informed consents were ob-
tained from the patients or their parents. Transverse serial fro-
zen muscle sections (7  m thickness) were stained with hema-
toxylin and eosin (H&E), modified Gomori trichrome, and a
battery of histochemical techniques (NADH-TR, ATPase
pH 9.4/4.6/4.3) were applied. All of them showed normal
immunostaining for three domains of dystrophin (N-termi-
nus, C-terminus and Rod-domain) on the muscle specimens,
and the deletion was not found on multiplex PCR for select-
ed exons of dystrophin gene. 
Immunocytochemical staining of muscle specimens
The tissues were processed for immunocytochemistry as
follows: the 7  m serial sections were fixed in acetone at 4℃
for 10 min, rinsed in 0.05 mol/L Tris-buffered saline (pH
7.5) for 15 min, and incubated for 30 min with a blocking
solution containing 2% bovine serum albumin and 5% nor-
mal goat serum as described (13). The sections were then
incubated overnight at 4℃ with one of the following anti-
bodies:  -sarcoglycan (NCL- -SARC, Novocastra),  -sarco-
glycan (NCL- -SARC, Novocastra),  -sarcoglycan (NCL- -
SARC, Novocastra),  -sarcoglycan (NCL- -SARC, Novo-
castra), dysferlin (NCL-DYSF, Novocastra),  -dystroglycan
(NCL- -DG, Novocastra, Newcastle Upon Tyne, U.K.), and
caveolin-3 (Transduction laboratory, Lexington, KY, U.S.A.).
These affinity-purified antibodies were well characterized and
did not cross-react with each other. After washing for 30 min
in Tris-buffered saline, the sections were examined using sec-
ondary goat anti-mouse IgG antibodies conjugated to perox-
idase and visualized by a DAB (diaminobenzidine)-peroxidase
reaction (Vector Laboratories, CA., U.S.A.). The sections were
also incubated with biotinylated goat anti-mouse IgG, which
was followed by fluorescent isothiocyanate (FITC) avidin D
(Vector Laboratory, CA., U.S.A.) for dysferlin.
RESULTS
Four (Patient No. 1-4) of the 17 ARLGMD patients group
(24%) showed a selective loss of dysferlin by both DAB and
DAB, diaminobenzidine; FITC, fluorescent isothiocyanate; DPH, dystrophin;  -SG,  -sarcoglycan;  -SG,  -sarcoglycan;  -SG,  -sarcoglycan; -
SG,  -darcoglycan; Dysf, dysferlin; Cav3, caveolin-3;  -DG,  -dystroglycan; +/-, decreased or weakly positive.
Patient No. Sex/Age (yr) DPH (DAB) -SG (DAB) -SG (DAB) -SG (DAB) -SG (DAB) Dysf (DAB) Dysf (FITC) Cav3 (DAB) -DG (DAB)
1 F/35 + + + + + -- ++
2 F/41 + + + + + -- ++
3 F/43 + + + + + -- ++
4 M/15 + + + + + -- ++
5 F/21 + + + + +/- ++ + +
6 M/40 + + + + + + + + +
7 M/13 + + + + +/- ++ + +
8 F/25 + + + + - +/- +++
9 M/5 + + +/- + - ++ + +
10 M/7 + + +/- + - ++ + +
11 M/17 + + + + + + +/- ++
12 M/10 + + + + + + + + +
13 M/5 + + + + + + + + +
14 F/10 + + + + + + +/- ++
15 F/9 + + - +/--++ / - ++
16 M/9 + + + + +/- ++ + +
17 M/23 + + + + + +/- +++
Table 1. The Immunocytochemical findings of the 17 ARLGMD patients
U/Ex, upper extremity; L/Ex, lower extremity; prox, proximal; dist, distal; CK, creatine kinase.
prox dist prox dist
U/Ex L/Ex
Face Neck
Serum CK 
level (IU/L)
Calf muscle 
hypertrophy
Bony
abnormality
Cardiac/pulmonary
insufficiency
Distribution of muscle weakness
Age at onset
(yr)
Sex/
Age
(yr)
Patient
No.
1 F/35 27 -- 44 + 44 + -- + (symmetric) 5310
2 F/41 26 -- 44 + 4 - 4 -- - 4010
3 F/43 33 -- 4+ 5 4 4+ -- - 4460
4 M/15 9 -- 4- 4+ 4- 4 -- + (symmetric) 4689
Table 2. The clinical and laboratory characteristics of the four LGMD2B patientsImmunocytochemistry in Patients with LGMD2B 449
FITC methods on the muscle specimen (Table 1). Therefore,
they were classified as having LGMD type 2B (LGMD2B).
Although three patients (patient No. 8-10) showed isolated
deficiency of  -sarcoglycan, it was regarded as a technical
error since the  -sarcoglycanopathy had always showed com-
bined deficiency of other sarcoglycans ( ,  , and  ) at exam-
Fig. 1. Muscle specimens of the quadriceps femoris muscle (from patient No. 1) stained by hematoxylin-eosin (A) and modified Gomori
Trichrome (B). There were great variation in the size of fibers, fiber splitting with internal nuclei, and clumps of small fibers (×200). 
A B
Fig. 2. Immunostaining against  -sarcoglycan ( -SG),  -sarcoglycan ( -SG), caveolin-3 (Cav-3), and  -dystroglycan ( -DG) on the
muscle specimen in the four LGMD2B patients by the diaminobenzidine (DAB)-peroxidase method. All four LGMD2B patients showed a
normal immunoreactivity against  -sarcoglycan,  -sarcoglycan, caveolin-3, and  -dystroglycan (×200). 
Case 1
-SG -SG Cav-3 -DG
Case 2
Case 3
Case 4450 S.-H. Oh, S.-W. Kang, J.-G. Lee, et al.
ination by immunocytochemistry (14). One patient (patient
No. 15) showed loss of  and  -sarcoglycan with partial defi-
ciency of  -sarcoglycan. This patient might be tentavely clas-
sified as  or  -sarcoglycanopathy although molecular genet-
ic diagnosis was not performed. 
Clinical characteristics and course of disease in four
patients with LGMD2B
The age of patients at the onset of the disease varied from
9 yr to 33 yr, and the disease duration ranged from 6 yr to
15 yr (Table 2). All four patients showed symmetrical proxi-
mal weakness. Although all the patients showed a function-
al disability in walking or running, none was wheelchair-
bound at the examination. While symmetrical hypertrophy
of the calf muscle was noted in two patients (patient No. 1 &
4), muscle atrophy was not found in any of the four patients.
None of the four patients had a cardiac or respiratory insuf-
ficiency nor did they have any bony abnormalities. The serum
creatine kinase (CK) level was elevated to approximately 20
times of the normal level in all the patients. (4010-5310
IU/L). One patient (patient No. 1) had a positive family his-
tory. One of her elder brother (41 yr old) had similar symp-
toms, which presented as a slowly progressive proximal weak-
ness over 15 yr. 
Pathological and immunocytochemical findings of 
muscle biopsy in four patients with LGMD2B
All the patients showed the following non-specific myo-
pathic changes in the muscle: increased internal nuclei, a few
or many atrophic fibers, degenerating fibers with regenerating
fibers, and an increased fiber size variation (Fig. 1). Type 1
fiber predominance (>60%) was noted in one patient (patient
No. 1). There was no endomysial or perivascular inflamma-
tory cell infiltrations in all the patients. 
In all the patients with LGMD2B, immunocytochemical
reaction against all the subtypes of sarcoglycans,  -dystro-
glycan, and caveolin-3 was normal (Fig. 2, Table 1), while
the reaction against dysferlin showed complete loss of reac-
tivity at the sarcolemma of the muscle fibers (Fig. 3).
DISCUSSION
The clinical features of our patients with LGMD2B was
similar to those of previous reports (12, 15-17). Symptoms
of the disease generally are manifested during the early adult-
hood (average onset is noted between the age of 17-30 yr), and
the disease generally has a benign course, and confinement
to a wheelchair may occur in approximately 10% of patients
(15, 18). Despite of the slow clinical evolution, extremely
high CK level (10-20 times of normal value) was characteris-
tic of LGMD2B, being indicative of protein’s role in normal
muscle homeostasis (“leaky” membrane) rather than being
essential for structural stabilization of the skeletal muscle
(6, 19). A few LGMD2B patients showed symmetrical or
asymmetrical calf muscle hypertrophy, as was observed in
two of the patients in this study. Up to date, only several esti-
mates of the frequency of dysferlinopathy exist. The propor-
tion of LGMD2B is thought to be relatively high in Brazil-
ian and Japanese population (estimated to be 19-25% of all
Fig. 3. Immunostaining against dysferlin
on the muscle specimens from the four
LGMD2B patients by a fluorescent isothio-
cyanate (FITC) technique. Normal control
(A) showed a positive immunoreactivity
against dysferlin at the sarcolemma. How-
ever, all four LGMD2B patients (B-E) show-
ed a complete absence of a reaction against
dysferlin at the sarcolemma on the muscle
specimen (×200).
A
D
B
E
CARLGMD cases) (15, 20) and there is founder mutation of
DYSF appears to be present in the Libyan Jews (17). How-
ever, another recent study reported a relatively lower frequen-
cy of the dysferlin deficiency in Caucasian patients with the
LGMD phenotype (approx. 1%), indicating a frequency varia-
tion according to the ethnicity (21). Although it is not enough
to estimate the frequency of LGMD2B in the Korean ARL-
GMD patients due to a small number of subjects, these results
suggest that the frequency of LGMD2B is relatively high
among ARLGMD in Korea. A detailed population-based
study will be needed to determine the exact frequency of
the LGMD2B in Korea. 
In all the cases with dysferlin deficiency, the immunocyto-
chemical study showed normal reactivity against dystrophin,
-,  -,  -,  -sarcoglycans,  -dystroglycan on muscle speci-
men, which suggests that there are no interactions between
dysferlin and the dystrophin-glycoprotein complex (DGC).
This finding is in accordance with previous studies (22, 23).
The DYSF is large, comprising 55 exons that span the geno-
mic region of >150 kb (24). Although direct gene analysis
provides the most reliable diagnosis, it is costly, time-con-
suming, and labor intensive because of the large size of the
DYSF. Moreover, defects in the dysferlin gene involve most-
ly single nucleotide changes with no common mutations,
gross rearrangements, or mutational hotspots that could aid
detection (2). For this reason, it would be better to initiate
screening for the dysferlin deficiency using antibodies against
this protein in muscle biopsies. Complete loss of dysferlin
without deficiency of other proteins appears to be specific
for primary dysferlinopathy on immunocytochemistry (24).
However, it should be noted that some cases with sarcogly-
canopathy, caveolinopathy can show partial deficiency of dys-
ferlin (secondary deficiency) (25, 26). Therefore, it is recom-
mendable to perform immunocytochemical analysis using
antibodies against other sarcolemmal proteins in addition to
the antibodies against dysferlin. When partial deficiency of
dysferlin is present on immunocytochemistry, direct sequenc-
ing of DYSF will be needed. 
In conclusion, the clinical, pathological, and immunocy-
tochemical findings of patients with LGMD2B in this study
were in accordance with those of previous reports. 
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